Search results for: Oncology

Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes

20 March 2012

…of life. At the Second Annual Oncology Market and Patient Access conference in January, Dr. Jorge Mestre-Ferrandiz presented preliminary results from OHE research in progress. It analyses appraisals of cancer…

OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development

4 October 2016, 11:00pm

…also developed the NICE scientific advice database. Prior to NICE Francois worked for the EMA for 15 years. His activities covered both pre- (registration of centrally authorised products in oncology,…

Foundation

…more difficult to find a new treatment for heart disease, it was that we already had treatments for heart disease and the industry was now shifting into oncology, which is…

Cell & Gene Therapy

…paradigm shift in oncology. Furthermore, they offer a lifeline for individuals grappling with rare diseases, often considered orphan diseases due to their limited patient population. Cell and gene therapies provide…

Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs

21 February 2019

…Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report. RePEc. Towse, A. and Garrison, L., 2017. Value assessment in precision cancer…

OHE at ISPOR Europe 2018

…Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology In the economic modelling of immunotherapies, the question arises of which utilities should be assigned…

What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?

9 July 2018

…progress stimulates competition and often leads to several products coming to market in a therapy class. This is particularly the case in recent developments in oncology. We propose that a…

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

29 April 2021

…not observable in clinical practice. For instance, a clinician cannot observe how changes in mortality rates in oncology might relate to changes in mortality rates in mental health. The authors…

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation 

14 September 2021

…technologies have not had the transformative effect that they have had in areas like oncology and genetic diseases. In these complex diseases, understanding of the disease and how therapeutics could…